CliffBio
biologic

Alhemo

concizumab-mtci

Loss of exclusivityDecember 2036projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameAlhemo
Active ingredientconcizumab-mtci
Strength150MG/1.5ML (100MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

More from Novo Nordisk Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Alhemo patent cliff — loss of exclusivity December 2036 | CliffBio